Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Their lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.


Biotechnology

Pharmaceutical

Sudo Biosciences

Scott Byrd

Imran B.

David Hennings

Anjali Pandey

Ian W. Mills

Gordon McMurray

Leadership Team

Operations Team

Teams at Sudo Biosciences

Leadership Team

Operations Team